The catalytic spliceosome inhibitor E7107 induces IR and has potent... | Download Scientific Diagram
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma - ScienceDirect
Scalable Synthesis of 17S-FD-895 Expands the Structural Understanding of Splice Modulatory Activity - ScienceDirect
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia | Leukemia
The catalytic spliceosome inhibitor E7107 induces IR and has potent... | Download Scientific Diagram
SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia
Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators | Nature Communications
E7107
Dysregulated Alternative Splicing Landscape Identifies Intron Retention as a Hallmark and Spliceosome as a Therapeutic Vulnerability in Aggressive Prostate Cancer | bioRxiv
E7107
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma | bioRxiv
Splicing modulators: on the way from nature to clinic | The Journal of Antibiotics
Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds - ScienceDirect
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance
A Comprehensive Overview of Structure‐Activity Relationships of Small‐Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents - Zhang - 2020 - ChemMedChem - Wiley Online Library
IJMS | Free Full-Text | Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers | HTML
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
2018 Bone Marrow Failure Highlight - A Novel Therapy for Targeting Acquired Bone Marrow Failure Diseases , Bone Marrow Failure Research Program, Congressionally Directed Medical Research Programs
Splicing modulation by E7107 treatment broadly affects the CLL... | Download Scientific Diagram
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma - eBioMedicine
Frontiers | Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease | Genetics
Cancers | Free Full-Text | Somatic Mutations in Core Spliceosome Components Promote Tumorigenesis and Generate an Exploitable Vulnerability in Human Cancer | HTML
IJMS | Free Full-Text | Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers | HTML
E7107 | CAS#630100-90-2 | spliceosome inhibitor | MedKoo
